Pelthos Therapeutics Inc.: 3i, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
3i, LP amended its Schedule 13G filing for Pelthos Therapeutics Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-126216. The filing, submitted on the short-form schedule reserved for passive investors, revises 3i's previously reported position in the company. Schedule 13G amendments are typically triggered when ownership crosses 5% thresholds or when a holder's stake changes materially, though the filing summary did not disclose the specific percentage involved. The update matters because it signals a shift in 3i's holdings that could draw attention from other institutional investors tracking Pelthos. What to watch next is the full filing detail, which should clarify whether 3i increased, trimmed or maintained its position and whether the change reflects passive portfolio rebalancing or a more deliberate stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Pelthos Therapeutics Inc., 3i, LP